This study was designed to measure certain cardiovascular effects of 2 or 11 μg nifedipine/kg body weight given intravenously to dogs anesthetized with fentanyl-droperidol-pentobarbital. Parameters measured were: cardiac output, stroke volume, stroke work, systemic arterial pressure and vascular resistance, splenic weight (a measure of venous capacitance), and fractionation of cardiac output to many tissues. In response to doses of nifedipine, systemic vascular resistance decreased, cardiac output and flows to most organs increased, and heart rate, stroke work, and splenic capacitance were unchanged. The flow to the diaphragm increased more than that to other organs.
Get full access to this article
View all access options for this article.
References
1.
Ellrodt G., Chew Cyc, Singh BN: Therapeutic implications of slow channel blockage in cardio-circulatory disorders . Circulation62:669-679, 1980.
2.
Stone DH, Antman EM, Muller JE, et al: Calcium channel blocking agents in the treatment of cardiovascular disorders. II. Hemodynamic effects and clinical implications. Ann Intern Med93:886-904, 1980.
3.
Guazzi M., Olivari MT, Polese A., et al: Nifedipine, a new antihypertensive with rapid action. Clin Pharmacol Ther22:528-532, 1977.
4.
Braunwald E. : Mechanism of action of calcium channel blocking agents. N Engl J Med307:1618-1627, 1982 .
5.
Hamlin RL, Ginaven SN, Smith CR, et al: Fetaryl citrate droperidol pentobarbital for intravenous anesthesia in dogs. J Am Vet Med Assoc152:360-364, 1968.
6.
Taylor RB, Brown CG, Bridges T., et al: Regional blood flow measurements during CPR in a swine model resuscitation. A model for regional blood flow measurements during cardiopulmonary resuscitation in a swine model. Resuscitation16:107-118, 1988.
7.
Hubbel JA, Muir WW: Effect of xylazine hydrochloride on canine splenic weight: An index of vascular capacity. Am J Vet Res43:2188-2192, 1982 .
8.
Nayler WG, Poole WP: Calcium antagonists: Definition and mode of action. Bas Res Cardiol55:1303-1307, 1985.
9.
White HD, Polak JF, Wynne J., et al: Addition of nifedipine to maximal nitrate and beta-adrenoreceptor blocker therapy in coronary artery disease. Am J Cardiol55:1303-1307, 1985.
10.
Betocchi S. , Bonow R., Cannon R III, et al: Relationship between serum nifedipine concentration and hemodynamic effects in nonobstructive hypertrophic cardiomyopathy . Am J Cardiol61:830-835, 1988.
11.
Elkayam U., Weber L., McKay CR, et al: Differences in hemodynamic response to vasodilation due to calcium channel antagonism with nifedipine and direct-acting agonism with hydralazine in chronic refractory congestion heart failure. Am J Cardiol54:126-131, 1984.
12.
Elkayam U., Weber L., Campese V., et al: Renal hemodynamic effects of vasodilation with nifedipine and hydralazine in patients with heart failure. J Am Coll Cardiol4:1261-1267, 1984.
13.
Polese A., Fiorentini C., Olivari MT, et al: Clinical use of a calcium antagonistic agent (nifedipine) in acute pulmonary edema. Am J Med66:825-830, 1979.
